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ABSTRACT 
Clear cell Renal Cell Carcinoma (ccRCC) 
represents the most common kidney cancer 
worldwide. Increased cell proliferation 
associated with abnormal microRNA 
(miRNA) regulation are hallmarks of 
carcinogenesis. Ankyrin repeat and single 
KH domain 1 (ANKHD1) is a highly 
conserved protein found to interact with core 
cancer pathways in Drosophila, however its 
involvement in RCC is completely 
unexplored. Quantitative PCR studies 
coupled with large-scale genomics data 
analyses demonstrated that ANKHD1 is 
significantly upregulated in kidneys of RCC 
patients when compared to healthy controls. 
Cell cycle analyses revealed that ANKHD1 is 
an essential factor for RCC cell division. To 
understand the molecular mechanism(s) 
utilized by ANKHD1 to drive RCC cell 
proliferation we performed bioinformatics 
analyses which revealed that ANKHD1 
contains a putative miRNA-binding motif. 
We screened 48 miRNAs with tumour-
enhancing or suppressing activities, and 
found that ANKHD1 binds to and regulates 
three tumour-suppressing miRNAs (i.e. miR-
29a, miR-205, and miR-196a). RNA-
immunoprecipitation assays demonstrated 
that ANKHD1 physically interacts with its 
target miRNAs via a single K-Homology 
(KH)-domain, located in the c-terminus of the 
protein. Functionally we discovered that 
ANKHD1 positively drives ccRCC cell 
mitosis via binding to and suppressing mainly 
miR-29a and to a lesser degree via miR-
196a/205, leading to an upregulation in pro-
proliferative genes such as CCDN1. 
Collectively, these data identify ANKHD1 as 
a new regulator of ccRCC proliferation via 
specific miRNA interactions.  
      
Introduction 
Renal cell carcinomas (RCCs) represent one 
of the commonest diagnosed cancers 
worldwide, with clear cell Renal Cell 
Carcinoma (ccRCC) accounting for 
approximately 80% of all RCCs. 
Molecularly, the tumour suppressor von 
Hippel-Lindau (VHL) is frequently 
inactivated by mutations (1), leading to 
increased proliferation, enhanced 
angiogenesis and de-differentiation of 
tumour cells. ccRCC pathogenesis is linked 
to abnormal regulation of certain microRNAs 
(miRNAs) (2,3). The latter are a class of ~22 
nucleotide-long, single-stranded non-coding, 
nucleic acid molecules involved in the 
regulation of proliferation (4,5). In ccRCC, 
the tumour-suppressor miR-29a is strongly 
downregulated and predicts metastasis (6). 
miR-29a, expressed by the kidney, is 
responsible for the regulation of extracellular 
matrix (7, 8) in addition to acting as a core 
regulator of cellular proliferation (9). The 
mechanisms and proteins that govern the 
control of the levels of miR-29a in ccRCC are 
currently unknown.  
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Ankyrin repeat and KH domain-containing 
protein 1 (ANKHD1), is a K homology (KH) 
containing protein first discovered in 
Drosophila as a genetic regulator of the 
EGF/MAPK pathway (10). It was later 
shown to regulate additional signalling 
cascades including the cancer-associated 
HIPPO (11-14) and PINK/Parkin in 
Drosophila (15). Clinical epidemiological 
studies suggested that ANKHD1 is elevated 
and may be involved in acute leukaemia (16) 
and prostate cancer (11). Despite these 
insights, the molecular mechanisms 
employed by ANKHD1 to exert these 
pleiotropic cancer-associated functions are 
as-yet-unidentified. 
ANKHD1 contains a single KH domain, a 
motif predicted to bind single-stranded 
nucleic acids. However, the function of the 
KH, including its potential ability to bind 
nucleic acids, has not been experimentally 
tested. Here, we report that ANKHD1 is 
elevated in patients with ccRCC and 
contributes to cancer cell proliferation via 
binding to and suppressing a number of 
tumour-suppressor miRNAs.  
Results  
ANKHD1 is overexpressed in renal cell 
carcinoma (RCC). 
Given that ANKHD1 regulates some cancer-
associated biochemical pathways we first set 
out to examine the expression of ANKHD1 in 
normal and RCC human kidneys. Using a 
commercially available rabbit polyclonal 
antibody, we found that anti-ANKHD1 
antibodies are strongly bound in tubular 
epithelial, parietal epithelial and renal 
microvascular cells with no detectable signal 
in fibroblasts nor glomerular cells in the 
normal mouse kidney (representative pictures 
shown in SI Figure 1A, n=5 animals). Similar 
findings were observed in normal human 
kidney sections stained with an anti-
ANKHD1 antibody (Figure 1A, left). To 
examine if ANKHD1 is expressed by kidney 
cancer cells we analysed its expression in 20 
different RCC cancer patients (Figure 1A, 
right panel and SI Figure 1B). Having 
established that ANKHD1 is expressed at the 
protein level in kidney cancer, we next 
wished to study whether kidneys of patients 
with renal cell carcinoma had altered 
ANKHD1 mRNA levels. We found a 
statistically significant elevation of 
ANKHD1 in RCC samples when compared 
to healthy control kidney tissues (Figure 1B). 
Furthermore, ANKHD1 mRNA levels were 
not significantly different between early (I/II 
- non-metastatic) and late stages (III/IV - 
metastatic) of cancer, suggesting that 
ANKHD1 is up-regulated early in the 
carcinogenesis process (Figure 1C). 
Consistent with our findings, bioinformatics 
analyses of the NIH cancer genome atlas 
using cBioPortal (17,18) showed that 33% of 
all ccRCC patients (of 538 patients) had 
significantly overexpressed ANKHD1 
mRNA levels, with 16% of patients 
exhibiting elevated ANKHD1 due to locus 
amplification 
(http://www.cbioportal.org/index.do?session
_id=59e0b593498e5df2e2969c52&show_sa
mples=false&); thus providing an 
explanation as to why ANKHD1 is elevated 
early in a large proportion of these patients.   
Taken together, these studies demonstrate 
that ANKHD1 is frequently upregulated in 
RCC when compared to healthy non-cancer 
renal tissues and may contribute to this 
disease.  
ANKHD1 controls cancer cell proliferation  
To better understand the function of 
ANKHD1 and examine whether it promotes 
or inhibits cancer-associated phenotypes, we 
initially tested its role in two independent 
renal cancer lines derived from ccRCC 
patients (RCC4 and 786-0). Two independent 
siRNAs targeting ANKHD1 mRNA were 
used and their efficiency tested by qPCR and 
western blotting (SI Figure 2A-B). Reduction 
of ANKHD1 by 70% or greater was used in 
all subsequent experiments. Given that 
ccRCCs are characterised by their 
proliferative nature, we decided to study 
whether ANKHD1 controls the ability of 
RCC cells to divide using Propidium-iodine 
stained cells by flow cytometry. In both renal 
cell lines tested and in each independent 
experiment, ANKHD1 silencing resulted in a 
significant reduction in the number of cells in 
G2-M phase, fewer cells in S phase, and a 
statistically significant increase in G1 phase 
(Figure 2A). Ultimately, for cancer cells to 
divide and propagate they need to undergo 
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mitosis, therefore to investigate whether 
ANKHD1 knockdown reduces mitosis, we 
studied phospho-serine10 Histone H3 (19) 
(subsequently referred to as pH3), which is a 
specific marker of mitosis. Loss of ANKHD1 
function, using two independent siRNAs in 
multiple experiments, resulted in a 
statistically significant reduction in the 
number of pH3 positive cells in both RCC4 
cells (Figure 2C and E) and 786-O cells 
(Figure 2D). Taken together, these results 
indicate that ANKHD1 is a positive regulator 
of proliferation in RCC-derived cancer cells 
in vitro, thus suggesting it contributes to 
disease. 
ANKHD1 reduces the expression of a subset 
of miRNAs 
We next set out to determine the molecular 
mechanisms underlying the pro-proliferative 
activity of ANKHD1. ANKHD1 contains a 
single K-Homology (KH) domain from 
amino acids 1694 to 1764. Given that other 
KH domain-containing proteins KSRP (20), 
RCF3 (21) and Bicc1 (22) were previously 
shown to bind to miRNAs, we set out to test 
whether ANKHD1 similarly controls 
proliferation via an interaction with miRNAs. 
To identify ANKHD1-relevant miRNAs, 
initially we measured the levels of 48 cancer-
associated miRNAs using a hybridization 
array in cancer cells with and without 
ANKHD1 silencing. We found ANKHD1 
siRNA resulted in enhanced expression of 
five miRNAs by greater than 2-fold (Figure 
3A, red box); while 4 miRNAs (namely, -
342, 1, 223 and -182) showed more than 2-
fold decreased when ANKHD1 was silenced 
(Figure 3A, black box).  
We then carried out qPCR analysis of miR-
29a-3p, miR-196a, miR-143, miR-122 and 
miR-205 and found that silencing of 
ANKHD1 resulted in a significant 
upregulation of all miRNAs identified in the 
array expect for miR-122 (Figure 3B). miR-
122, whilst it showed a 11-fold increase in the 
array (Figure 3A), it did not change 
significantly in our independent qPCR 
validation experiments (Figure 3B), 
suggesting that it is likely to represent a false 
positive in the initial assay, due to a technical 
artefact. As a control, we also tested miR-15a 
(Figure 3B), which did not show a significant 
change, as expected from the array results 
(Figure 3A, green box). Collectively, our 
findings indicate that ANKHD1 controls 
expression of a subset of miRNAs, including 
miR-29a-3p. 
ANKHD1 physically associates with miR-
29a-3p, -196a, and -205 via its KH domain. 
ANKHD1 contains two clusters of ankyrin 
repeats, which have previously been shown 
to mediate protein-protein interactions, and a 
single KH domain - a motif predicted to bind 
to single-stranded nucleic acids (23). 
Therefore, theoretically, if ANKHD1 
interacts with miRNAs this interaction may 
be mediated via its KH domain, or 
alternatively, ANKHD1 may associate with a 
miRNA-binding protein complex via its 
ankyrin domains. In the first instance, we 
tested whether endogenous full-length 
ANKHD1 is capable of binding miRNAs by 
undertaking endogenous RNA 
immunoprecipitations (RIP). The efficiency 
of the ANKHD1 pull-down was checked by 
Western blotting indicating that ANKHD1 is 
pulled down effectively when an anti-
ANKHD1 antibody is used by not with IgG 
control, the identity of ANKHD1 was also 
validated by a single siRNA against 
ANKHD1 (SI Figure 2C). We found a 
statistically significant enrichment of miR-
29a-3p, miR-196a and miR-205 in ANKHD1 
pull-downs when compared to IgG control 
antibodies (Figure 4A), indicating that 
ANKHD1 physically associates with these 
miRNAs. While, not surprisingly, ANKHD1 
antibodies were not able to pull-down miR-
122, one of the miRNAs with false positive 
results (SI Figure 2D), confirming the 
specificity of the RNA-immunoprecipitation 
approach. In order to test whether the full-
length ANKHD1 molecule binds to miRNAs 
directly, via its KH domain, or indirectly, via 
its ankyrin repeats, we generated and 
overexpressed flag-tagged constructs. A full-
length flagged-tagged wild type ANKHD1 
construct (FL-WT) was used to generated a 
truncation construct which we termed KH-
WT, this construct lacked the N-terminal 
region of the protein but maintained the C-
terminus with an intact KH domain (KH-WT) 
(Figure 4B). We transfected these constructs 
into cells and performed RIP assays which 
showed that the KH-WT was able to 
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physically associate with miR-29a-3p (Figure 
4E) and miR-196a (Figure 4F) to a level 
comparable to that observed with FL-WT 
ANKHD1 (compare bar 2 with 4), thus 
indicating that the N-terminal portion of the 
protein (which contains the ankyrin repeats) 
is not required for this interaction. Having 
shown that the ankyrin domains are 
redundant for the miRNA interaction we next 
examined whether there was a functional unit 
within the KH domain that directly mediated 
the nucleic acid binding. Previously a GxxG 
loop within KH domains of other proteins 
was identified to be critical for mediating 
miRNA interactions (24). We searched the 
KH sequence of ANKHD1 and found a 
canonical GxxG loop which exhibited 100% 
amino acid conservation between humans, 
mouse and Drosophila (SI Figure 2E), 
suggesting an important biological role. We 
next went on to create a 2-amino acid 
mutation within this loop, which generated a 
GDDG structure (FL-Mut), previously 
shown to exhibit reduced nucleic acid 
binding ability without compromising protein 
stability (24,25), we confirmed the mutation 
by sequencing (Figure 4C). We, next 
overexpressed both FL-WT and FL-Mut 
versions of ANKHD1 and performed RIP 
assays. We found that the FL-Mut construct 
possessed reduced RNA binding ability 
(Figure 4D-E), thus suggesting that 
ANKHD1 binds its targets miRNAs via the 
GxxG loop of its KH domain.  
Functionally, to test whether an intact 
ANKHD1-GxxG loop is required to mediate 
the proliferative functions of ANKHD1, we 
forced expressed FL-WT or mutant FL-Mut 
ANKHD1 in RCC4 cells. Consistent with 
previous knock-down experiments, forced 
expression of FL-WT was sufficient to 
increase the proportion of cells undergoing 
mitosis, while transfection with the FL-Mut 
reduced proliferation compared to empty 
vector (EV) (Figure 4F), thus suggesting that 
ANKHD1 mediates its pro-proliferative 
actions via its GxxG loop.  
Taken together, these data demonstrate that 
ANKHD1 physically associates with its 
target miRNAs via its single KH domain and 
that mutations in this region are capable to 
abolish miRNAs binding and further abolish 
the ability of ANKHD1 to enhance 
proliferation of ccRCC cells. 
ANKHD1 regulates proliferation of cancer 
cells via miR-29a-3p. 
Given the significant alterations in miRNA 
levels mediated by ANKHD1, we 
hypothesized that ANKHD1 may exert its 
pro-proliferative effects via regulating one or 
more of the miRNAs identified above. 
Firstly, to test whether miR-29a is 
significantly reduced in RCC, as previously 
suggested, we performed qPCR analysis 
which confirmed that miR-29a is indeed 
downregulated in RCC (SI Figure 2F). As a 
starting point, we searched the Mirtarbase 
database for experimentally validated mRNA 
targets of miR-29a-3p, miR-196a and miR-
205 (SI Table 1). We then queried the 
annotation of these targets using the David 
functional annotation tool and found that 
Ôregulation of cell proliferationÕ was a 
statistically significantly enriched gene 
ontology (GO) term for miR-29a-3p (9 target 
genes) and miR-205 (4 target genes) but not 
for miR-196a (SI Table 1). Since miR-29a-3p 
is associated with the greatest number of 
proliferation-regulating genes, we started by 
testing whether it may mediate the 
proliferative effects of ANKHD1. We firstly 
knocked-down ANKHD1 in RCC4 cells 
transfected with either a miScript microRNA 
inhibitor targeting miR-29a-3p or an empty 
vector control (Figure 5A). As expected, 
silencing of ANKHD1 reduced the 
proportion of pH3 positive RCC4 when 
compared to non-target RNAi treated cells 
(NT si) (Figure 5B). Importantly transfection 
of a miR-29a-3p inhibitor did not affect the 
proliferation of RCC4 cells on its own 
(Figure 5B), however, co-transfection of the 
miR-29a-3p inhibitor together with knocking 
out ANKHD1 was capable of completely 
relieving the block in proliferation mediated 
by silencing of ANKHD1, thus restoring cell 
division to basal levels (Figure 5A-B). This 
suggested that miRNA-29a-3p suppression is 
required for ANKHD1 to promote mitosis in 
ccRCC cells. To check whether ANKHD1 
regulates proliferation via miR-29a-3p in an 
additional RCC-derived cell-line, 786.O cells 
were transfected either with ANKHD1 
siRNA on its own or co-transfected with an 
miR-29a-3p inhibitor. Consistent with 
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previous observations in RCC4 cells, co-
transfection of miR-29a-3p inhibitor in 786.O 
cells was sufficient to enhance proliferation 
when ANKHD1 was concomitantly silenced, 
suggesting that the suppression of miR-29a-
3p is a key mechanism employed by 
ANKHD1 to drive proliferation in RCC-
derived cancer cells.  
In addition to miR-29a-3p ANKHD1 
regulates miR-205 and 196a too. To examine 
if the proliferative effects of ANKHD1 are 
only via miR-29a-3p or whether these other 
miRNAs also play a role, we silenced 
ANKHD1 and transfected either with miR-
196a inhibitor an miR-205 inhibitor. We 
found that miR-205 / miR-196a inhibition 
caused a marginal increase in proliferation 
(Figure 5C). These results collectively 
suggest that the main proliferative 
mechanism employed by ANKHD1 is 
suppression of miR-29a-3p and to a lesser 
degree miR-205/196a.  
Finally, to test how silencing of ANKHD1 
may be driving a reduced proliferation of 
RCC cells, we silenced ANKHD1 using two-
independent siRNAs and tested by qPCR the 
expression of CCDN1, VEGFA and KLF4, 
three well-characterised targets of miR-29a-
3p. We found that ANKHD1 loss-of-function 
led to a statistically significant reduction of 
each of these genes, a phenomenon that could 
be restored by inhibiting miR-29a-3p (Figure 
5D).  
These data together suggest that ANKHD1 is 
a positive regulator of proliferation in renal 
cancer cells via suppressing primarily miR-
29a-3p and to a lesser degree via miR-
205/miR-196a, thus altering a number of 
known proliferation altering genes such as 
CCDN1.  
DISCUSSION 
Here we presented the first study assigning 
control of cancer cell proliferation as a 
molecular function of ANKHD1 in ccRCC. 
We showed that ANKHD1 controls renal 
cancer cell proliferation by engaging with 
and altering the levels of a subset of tumour-
suppressing miRNAs. We demonstrated that 
ANKHD1 physically forms a complex with 
three target miRNAs (namely miR-29a-3p, 
miR-205 and miR-196a) via its KH domain, 
which leads to a significant reduction in the 
levels of these miRNAs. Indeed, silencing of 
ANKHD1 leads to an increase of these 
miRNAs and inhibition of these restores the 
proliferative potential of cancer cells. Finally, 
we provide the first demonstration that 
ANKHD1 mRNA and protein are 
significantly enhanced in human ccRCC 
when compared to control, and may play an 
important role, in human ccRCC. 
Previous studies have convincingly 
demonstrated that miR-29a, miR-196a and 
miR-205 possess tumour-suppressor 
activities and are frequently, and 
significantly, down regulated in RCCs (6,26-
31), a finding that correlates with the 
upregulation of ANKHD1, demonstrated 
here. Furthermore, given that single 
inhibition of miRNA-29a is sufficient to 
restore the proliferation of RCC cells lacking 
ANKHD1, we suggest that miR-29a-targeted 
genes are likely to be responsible for the 
ANKHD1-mediated proliferation of ccRCCs. 
miR-29a has been previously shown to 
downregulate many proliferation-regulating 
genes including BCL2, CDC42, CCDN1, 
CCNT2, CDK2, CDK6, NASP, VEGFA and 
KLF4 (32-37). Indeed, we were able to show 
that ANKHD1 regulates CCDN1, VEGFA 
and KLF4 via miR-29a-3p further 
implicating suppression of miR-29a-3p as the 
main mechanism employed by ANKHD1 to 
control proliferation of renal cancer cells. 
CDC42 did not change significantly (SI 
Figure 1E).  
The other two miRNAs identified as binding 
partners of ANKHD1 are miR-196a and miR-
205. We found that ANKHD1 silencing leads 
to an increase in miR-196a and 205, and it 
physically interacts with these miRNAs. One 
of the main functional roles of ANKHD1, 
uncovered by this study, is the control of 
renal cancer cell-cycle. Yet, our experimental 
data only found a marginal role for miR-
196a/205 in the control of proliferation. This 
is consistent with our bioinformatics 
functional annotation of miR-196a/205, 
using validated targets, which did not reveal 
a major proliferation-regulating role for these 
miRNAs. Interestingly, miR-196a was 
previously shown to have a role in autophagy 
instead (38). This is particularly interesting 
because ANKHD1 was previously shown to 
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control autophagy in Drosophila (15). Thus, 
we speculate that ANKHD1 may have 
important, but yet-unidentified, additional 
molecular functions in mammalian cells, 
including ccRCC, one of which could be the 
control of autophagy. We therefore 
hypothesize that these additional molecular 
functions of ANKHD1 may be mediated via 
the suppression of miRNA molecules, some 
of which are identified in this study (e.g. 
miR-196a/205).  
Despite a clear role in the regulation of 
miRNA levels, the mechanism via which 
ANKHD1 leads to the potent downregulation 
of its target miRNAs is currently unclear. 
Although a simple ÔtrappingÕ model may 
appear attractive, we would expect that 
miRNAs tightly bound to ANKHD1 in an 
inactive complex would still be detectable in 
Trizol-derived total RNA extracted from 
whole cells. Rather, the accumulation of 
miRNAs following ANKHD1 knockdown 
together with the evidence that ANKHD1 
physically interacts with some of its targets 
suggests that ANKHD1 may promote 
destruction of the identified miRNAs or 
alternatively control their level of 
transcription Ð however the mechanism 
underlying this process is as-yet-unknown. 
Interestingly ANKHD1 has been shown to 
physically interact with factor inhibiting HIF 
(FIH) (39), a molecule that alters hypoxia 
inducible factor (HIF) transcriptional 
activity; HIF is involved in the development 
of ccRCC (40,41). Moreover, HIF controls 
cell cycle in hypoxia partly via controlling 
p21 amongst other targets (42). Interestingly 
ANKHD1 has been shown to interact with 
p21 (43), a finding which we confirmed in 
our study (SI Figure 1C-D). Therefore, 
ANKHD1 may alter proliferation and other 
related cancer phenotypes via multiple 
mechanisms; including the regulation of 
miRNAs and also potentially via control of 
HIF signalling.  
In conclusion, this study combines 
functional, biochemical and bioinformatics 
approaches to collectively demonstrate that 
ANKHD1 controls proliferation of renal cell 
carcinoma cells via binding to and 
modulating a specific subset of ccRCC-
relevant tumour-suppressor miRNAs. Further 
studies using miRNA modulating agents 
(mimics or inhibitors) and ANKHD1 
knockout animal models are required to 
determine the genetic role of ANKHD1 in 
this cancer.  
Experimental procedures 
 
Cell culture and transfections 
Human renal cancer cells 786.O were 
purchased from ATCC while human renal 
clear cell carcinoma cells (RCC4) with empty 
vector were purchased from Sigma and 
maintained in Dulbecco modified Eagle 
medium supplemented with 10% foetal calf 
serum, 2mM GlutaMAX without antibiotics 
at 37oC in a humidified incubator with 5% 
CO2. Cells were trypsinised and reversed 
transfected with 20pmol RNAi with RNAi 
MAX transfection reagent following 
manufacturerÕs instructions (Invitrogen). 
Two independent siRNAs were used for 
ANKHD1, with the following catalogue 
numbers: D-014405-01 and D-014405-03. In 
every siRNA experiment control cells were 
treated with non-target RNAi complexes (D-
001210-01). Anti- miR29a-3p inhibitor was 
purchased from Qiagen (3p, MIN0000086) 
and cells were transfected using 20pmol 
inhibitor with RNAi MAX. For plasmid 
transfection, a forward transfection, 12 hours 
after seeding was performed with 
Lipofectamine 2000 (Invitrogen) following 
manufacturerÕs instructions.  
 
RNA immunoprecipitation (RIP) 
RIPs were performed using Magna RIP kit 
(upstate, 70-700), following a modified 
version of the manufacturerÕs instructions. 
Briefly, around 2.5x10
7
 cells were used per 
immunoprecipitation, after washing the cell 
monolayer, cells were collected by 
centrifugation and lysed in RIP lysis buffer 
containing RNase inhibitor and incubated on 
ice for 5 min, cells were then placed at -80
o
C 
to allow cell lysis to take place. 
Immunoprecipitation using either rabbit anti-
ANKHD1 antibody (sigma, HPA008718) or 
anti-flag M2 antibody (sigma, A2220) or 
relevant rabbit or mouse IgG was used in a 
pull-down experiment, for 4 hours at 4
o
C 
with rotation. Then, after thoroughly washing 
of the beads, total RNA was extracted using 
TriZol and reversed transcribed immediately. 
Any remaining RNA was stored at -80
o
C.   
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Western blotting, Immunoprecipitation 
and antibodies 
Following specific treatment, a confluent 
monolayer of cells was washed twice in ice-
cold Tris-phosphate-buffered saline 
(1xTBS), TBS was aspirated and cells were 
lysed using ice-cold Lysis Buffer (50mM Tris 
(pH 7.4) 250mM NaCl, 0.3% Triton X-100, 
1mM ETDA) supplemented with protease 
inhibitor cocktail (Roche). Cells were then 
subjected to freeze-thaw and mild sonication. 
Whole cell lysates were then incubated with 
appropriate antibodies or isotype specific IgG 
control for 4 hours at 4
o
C followed by 
overnight incubation with Dynabeads Protein 
G (Life Technologies). Beads were then 
washed four times in cold Lysis Buffer and 
boiled in 2x Laemmeli sample buffer for 5 
minutes. Samples eluted from the beads or 
whole cells lysates were resolved by SDS-
polyacrylamide gel electrophoresis and 
transferred using the Mini-PROTEAN 
system (Bio-Rad). Primary antibodies were 
rabbit polyclonal anti-ANKHD1 
(HPA008718, Sigma), and mouse 
monoclonal anti-β-actin (ab8226, Abcam).  
 
Flow cytometry 
Cells were reverse transfected with 20nM of 
either ANKHD1 siRNAs or non-target 
siRNA and grown in 6 well plates for 72 
hours. On the day of the assay cells were 
lifted off the 6 well plate using Accutase 
solution (A6964, Sigma UK), re-suspended 
in DMEM with 10% FBS and centrifuged at 
200g for 5 minutes to pellet cells. Supernatant 
was discarded and cell pellets were re-
suspended in 50µl of 1xTBST by pipetting up 
and down at least 5 times, followed by 
addition of 1ml of ice-cold 100% methanol 
(kept at -20
o
C), cells were then immediately 
placed in the freezer and left for 30 minutes 
to allow adequate fixation. Following 
fixation cells were washed twice in 1xTBST 
and then either isotype control antibody 
(9078, Cell Signalling Technology), no 
antibody, or phosphorylated histone H3-
pacific blue conjugated antibody (1:125) 
(8552, Cell Signaling Technology) were 
added to cells and left to incubate in the dark 
at room temperature for 60 minutes. After 
this incubation cells were transferred into 
flow cytometry tubes and were analysed 
using LSRII running BD FACS Diva 
software. 10,000 events were recorded in the 
forward and side scatter and from these a gate 
was placed on single cells to eliminate 
doublets and clumps from analysis. From 
these a clear positive population could be 
seen and percentage of positive cells obtained 
by gating this population. Percentage of 
positive cells out of the 10,000 events was 
plotted on Prism 6.0 from three different 
biological replicates and a student t-test was 
carried out. P values of 0.05 or lower were 
considered significant. 
 
Quantitative PCR 
Total RNA was extracted using TRIZOLR 
reagent (Invitrogen) following 
manufacturerÕs instructions. Total RNA was 
then reverse transcribed using miScript RT 
kit, Qiagen, 218193. qPCR was carried out 
using and iQ SYBR green supermix reagents 
(Bio-Rad) following manufacturerÕs 
instructions on a CFX-96 or CFX-384 Touch 
Real-time PCR detection system (Bio-Rad). 
Change in expression levels was calculated 
relative to either β-actin housekeeping gene 
(for mRNA) or U6 (for miRNA) using the 
ddCT method. Primers used are:  
ANKHD1: forward: 5Õ 
AGCGGTACGGGCGGAG 3Õ, reverse: 5Õ 
AAATAAATGATTCAACCTCGGACAC 
3Õ;  
b-actin: forward 5Õ 
ATCATTGCTCCTCCTGAGCG 3Õ; 
reverse: 5Õ GACAGCGAGGCCAGGATG 
3Õ.  
MiRNA hybridization plate and human 
RCC cancer tissue arrays 
To identify targets of ANKHD1 a miRNA 
hybridization plate array was used (Signosis, 
MA-1001). 20µg of RNA (either from cells 
with non-target RNA or siRNA against 
ANKHD1) was added to each well and 
incubated overnight, the array was then 
analysed using manufacturerÕs instructions. 
To study the mRNA levels of ANKHD1 or 
miR29a in human RCC patients and healthy 
controls a tissue scan Kidney Cancer Tissue 
qPCR array was used (Origene, HKRT102), 
and qPCR was performed following 
manufacturerÕs instructions (using primers 
stated above). To study protein levels of 
ANKHD1 in RCC an array of 20 independent 
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cases of RCC and 60 cores (each case 
repeated three times) was utilised (BC07013, 
US biomax). Tissues were deparaffinised and 
IHC performed as previously described, these 
studies abide by the Declaration of Helsinki 
principles and tissues were collected under 
HIPAA approved protocols (44).  
 
Statistics 
All experiments were repeated at least three 
times unless otherwise stated. GraphPad 
prism 6 was used to input data and either non-
parametric, two-tailed, Mann-Whitney tests 
were performed or for two sample 
comparison a student t-test was used. P 
values less than 0.05 were recorded as 
significant. 
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Figure 1: ANKHD1 is expressed by renal epithelial cells and is overexpressed in renal cell 
carcinoma patients 
A. A human array of kidney tissues with 20 cases of RCC and 3 control non-cancer tissues 
were stained with an anti-ANKHD1 antibody and microscopy performed using an upright 
Olympus microscope. B. Haematoxylin and Eosin (H&E) staining of the above matching 
tissues can be seen. C. qPCR was performed for ANKHD1 normalised to b-actin for non-
cancer kidney tissue when compared to renal cell carcinoma. D. Sub-group analysis of the 
ANKHD1 expression in the RCC patient population was unable to identify any differences in 
the expression in the early (I/II) versus late stages of disease (III/IV). Error bars show mean 
and standard error of the mean. There is a significant difference in expression in ANKHD1 
message in RCCs when compared to healthy control subjects (B) while there is no difference 
in expression between early and later stages of cancer (C), when analysed by a student t-test. 
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!
Figure 2: ANKHD1 is required for the proliferation of 786.O and RCC4 renal cancer cells. 
A. Either 786.O (left) or RCC4 (right) cells transfected with ANKHD1 siRNA or non-targeting 
RNAi control were fixed and stained with Propidium iodine, the numbers of cells in the 
different stages of the cell cycle were counted by performing flow cytometry cell-cycle based 
analyses. Three independent transfection experiments are shown with standard error of the 
 by guest on A
pril 30, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
	 15	
mean. There is a statistically significant increase in G1 and a decrease in S/M phase of the cell 
cycle when the data were analysed by a one-way Anova with Bonferroni corrections. B-C. 
Either 786.O cells (B) or RCC4 (C) were treated with indicated siRNAs and stained with 
antibody that recognises p-serine10 histone H3 (pH3). pH3 positive cells were gated and 
percentage of positive cells identified. Isotype fluorotope matched control was used as a 
negative control. A statistically significant reduction in mitotic cells is observed in both 786.O 
cells (D) and RCC4 cells (E), all experiments were performed three times and P values of less 
than 0.05 were considered significant, using a one-way-Anova.  
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Figure 3: ANKHD1 regulates expression of a subset of tumour-suppressing miRNAs.  
A. RNA from cells treated with either a non-targeting siRNA or ANKHD1 siRNA was 
hybridized in a 48-miRNA hybridization plate, the levels of these miRNAs are shown following 
normalisation to U6. MiRNAs showing more than 2-fold increase are highlighted in the red 
box (above) and those exhibiting more than 2-fold decrease in the black box (below). miR-15 
which did not show a change is also highlighted in green.   
B. The expression of specific miRNA identified in A were verified by carrying out independent 
transfections followed by qPCR in RCC4 cells transfected with either non-targeting siRNA or 
ANKHD1 siRNA. All experiments were performed three times and P values of less than 0.05 
were considered significant using a student-t-test. 
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!
Figure 4: ANKHD1 binds to miR-29a-3p, -196a and -205 via its single KH domain.  
A. Endogenous RNA immunoprecipitations (RIP) for miR-29a-3p, -196a and 205 were 
performed using anti-ANKHD1 or IgG control antibodies, results are presented as fold 
enrichment over IgG. All experiments were performed three times and P values of less than 
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0.05 were considered significant using a student-t-test. B. A full-length flagged-tagged 
ANKHD1 construct (FL-WT) was used to generate a truncation mutation, a flag-tagged version 
of ANKHD1 that lacks the ankyrin repeats (KH-WT, 16kD). The canonical GxxG loop was 
mutated to GDDG to produce a flagged-tagged full-length mutant construct (FL-Mut). C. 
Sequencing was carried out to confirm the mutation in the FL-Mut construct. D-E. RIP pull 
downs were performed in RCC4 cells following transfection of either FL-WT, or FL-mut or 
KH-WT constructs. qPCR analysis of either miR-29a-3p (D) or miR196a (E) revealed that 
these physically interacted the full-length protein as well as the KH only proteins but were 
unable to interact with the mutant construct (FL-mut). F. RCC4 were transfected either with an 
empty vector (EV) or ANKHD1 full length (FL-WT) or the full-length mutant (FL-Mut) and 
cells stained with pH3 and subjected to flow cytometry to measure mitosis. Experiment was 
performed three times and a P value of less than 0.05 was considered as significant using a one-
way Anova.  
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!
Figure 5: ANKHD1 regulates proliferation via miR-29a-3p/miR-205 and to a lesser degree 
miR-196a.  
A. RCC4 cells were transfected with either Non-target (NT) or ANKHD1 siRNA (ANKHD1 
si) and co-transfected with an miR-29a-3p inhibitor. The number of RCC4 cells undergoing 
mitosis was studied by flow cytometry measuring number of pH3 positive cells. B. Experiments 
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were repeated three times and a P-value of less than 0.05 was considered as significant using a 
one-way Anova. C. ANKHD1 was also silenced in 786.O cells using two independent siRNAs 
(C, top panel) and number of mitosis measured. Inhibition of miR-29a (left) or miR-196a 
(middle) or miR-205 (right) was studied (C). D. To study how ANKHD1 control proliferation 
of 786.O cells, ANKHD1 was silenced using two independent siRNA and the expression of 
CCDN1, VEGFA and KLF4 was measured by qPCR. In addition to test whether the modulation 
of the target mRNAs is via miR-29a, cells were contransfected with a miR-29a-3p inhibitor. 
Results are normalised against HPRT expression and are shown as fold change when compared 
to non-target (NT) siRNA transfected cells. Experiments were repeated three times and a P-
value of less than 0.05 was considered as significant using a one-way Anova. 
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